Nutex Health Inc (NUTX)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ
Market Cap: $1.19B
Last updated: Nov 17, 2026 at 11:06 AM ET
Nutex Health Inc (NUTX) Financials: Revenue, Profit and Cash Flow
Nutex Health reported revenue of $875.26M for the fiscal year ended Dec 31, 2025, up 82.4% from the year before. That year, net income was $180.36M with a net margin of 20.6%, operating cash flow was $248.13M and free cash flow was $245.60M. The quarter ended Sep 30, 2026 had revenue of $217.61M and net income of $57.34M.
Revenue and Margins
The operating margin was 31.5% in the fiscal year ended Dec 2025. Over the 8 years to Dec 2025, revenue grew from $53.65K, a compound annual rate of 236.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $875.26M | +82.4% | 50.8% | 31.5% | 20.6% |
| Dec 2024 | $479.95M | +93.8% | 40.9% | 27.2% | 19.8% |
| Dec 2023 | $247.65M | +12.9% | 14.0% | -12.8% | -17.5% |
| Dec 2022 | $219.29M | -33.9% | 7.0% | -185.4% | -197.3% |
| Dec 2021 | $331.53M | +21.0% | 54.1% | 51.4% | 50.8% |
| Dec 2020 | $274.03M | +19954.5% | 57.5% | 55.9% | 53.1% |
| Dec 2019 | $1.37M | +1395.4% | 39.2% | -504.8% | -520.8% |
| Dec 2018 | $91.37K | +70.3% | 31.8% | -2003.4% | -3080.0% |
| Dec 2017 | $53.65K | N/A | 100.0% | -10611.8% | 1085.0% |
| Dec 2016 | N/A | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, net income rose 90.2% from the year before. In the quarter ended Sep 2026, net income fell 40.8% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $875.26M | $479.95M | $247.65M | $219.29M | $331.53M | $274.03M | $1.37M | $91.37K | $53.65K | N/A |
| Cost of revenue | $175.32M | $132.81M | $122.53M | $123.90M | $106.04M | $10.48M | $830.44K | $62.30K | $564.37K | $473 |
| Gross profit | $444.28M | $196.26M | $34.77M | $15.42M | $179.28M | $157.61M | $535.98K | $29.07K | $53.65K | -$473 |
| Research and development | $0 | $0 | $0 | $0 | $0 | $0 | $768.10K | $0 | $0 | $0 |
| Operating income | $275.63M | $130.70M | -$31.77M | -$406.60M | $170.26M | $153.17M | -$6.90M | -$1.83M | -$5.69M | -$448.60K |
| Net income | $180.36M | $94.81M | -$43.42M | -$432.74M | $168.53M | $145.56M | -$7.12M | -$2.81M | $582.06K | -$7.43M |
| EBITDA | $287.54M | $148.73M | -$14.58M | -$394.03M | $183.35M | $158.07M | -$6.73M | $0 | $0 | $0 |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $217.61M | $210.75M | $216.49M | $151.68M | $267.80M | $243.99M | $211.79M | $257.62M | $78.80M | $76.08M | $67.45M | $69.67M |
| Gross profit | $101.53M | $141.28M | $91.73M | $46.14M | $154.88M | $124.92M | $118.34M | $141.63M | $21.92M | $22.56M | $10.16M | $13.21M |
| Operating income | $77.10M | $121.72M | $81.27M | $30.92M | $130.37M | $33.68M | $80.66M | $114.29M | $9.66M | $5.30M | $1.45M | -$26.15M |
| Net income | $57.34M | $96.32M | $62.76M | $16.61M | $96.80M | $16.14M | $50.81M | $99.50M | -$7.17M | $3.01M | -$542.00K | -$27.71M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $43.25M by $142.32M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $918.52M | $655.32M | $398.25M | $431.75M | $394.65M | $169.86K | $6.69M | $449.43K | $3.33M | $510.83K |
| Current assets | $538.81M | $292.48M | $90.85M | $97.97M | $154.02M | $157.06K | $1.24M | $305.42K | $55.08K | $507.93K |
| Cash and equivalents | $185.57M | $40.64M | $22.00M | $34.26M | $36.12M | $26.93K | $1.07M | $119.27K | $9.45K | $10.52K |
| Total liabilities | $495.09M | $466.79M | $319.14M | $311.42M | $203.07M | $1.30M | $4.83M | $1.95M | $959.78K | $6.38M |
| Short-term debt | $14.08M | $17.95M | $14.18M | $15.17M | $10.23M | $312.89K | $2.48M | $477.06K | $386.19K | $50.00K |
| Long-term debt | $29.17M | $22.47M | $26.31M | $23.05M | $78.82M | $150.00K | $0 | N/A | N/A | N/A |
| Shareholder equity | $329.45M | $132.44M | $61.45M | $95.86M | $114.65M | -$1.13M | $1.86M | -$1.50M | $2.37M | -$5.87M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.03B | $964.63M | $957.32M | $918.52M | $964.52M | $841.03M | $761.92M | $655.32M | $438.49M | $422.40M | $404.28M | $398.25M |
| Total liabilities | $491.47M | $457.32M | $515.26M | $495.09M | $526.49M | $504.15M | $506.65M | $453.43M | $358.71M | $340.38M | $324.27M | $319.14M |
| Cash and equivalents | $249.91M | $205.21M | $207.35M | $185.57M | $166.05M | $96.73M | $84.73M | $43.58M | $46.91M | $40.81M | $30.01M | $22.00M |
| Shareholder equity | $435.57M | $394.32M | $346.29M | $329.45M | $317.17M | $235.25M | $176.95M | $146.34M | $60.44M | $62.73M | $63.02M | $61.45M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 99.0% of operating cash flow. Dividends and share repurchases together came to 32.3% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $248.13M | $23.15M | $1.26M | $50.61M | $173.43M | $86.67M | -$4.04M | -$480.05K | -$714.62K | -$274.22K |
| Capital expenditures | $2.53M | $2.30M | $9.50M | $14.63M | $36.93M | $61.19M | $84.00K | $0 | $0 | $0 |
| Free cash flow | $245.60M | $20.85M | -$8.24M | $35.97M | $136.51M | $25.48M | -$4.12M | -$480.05K | -$714.62K | -$274.22K |
| Dividends paid | $74.28M | $6.44M | $5.21M | $51.23M | $144.34M | $59.05M | $18.90M | N/A | N/A | N/A |
| Share repurchases | $5.00M | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | -$5.24M | -$5.61M | -$11.24M | -$4.34M | -$36.98M | -$61.19M | -$748.20K | -$116.96K | $2.05K | -$9.99K |
| Financing cash flow | -$97.95M | $1.09M | -$2.27M | -$48.13M | -$125.85M | -$7.97M | $5.73M | $704.57K | $711.50K | $172.44K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $78.35M | $34.20M | $75.52M | $70.39M | $99.51M | $27.26M | $50.97M | $54.00K | $6.79M | $13.26M | $3.05M | -$1.78M |
| Capital expenditures | $5.20M | $2.54M | $1.20M | $1.41M | $302.00K | $751.00K | $64.00K | $395.00K | $617.00K | $559.00K | $733.00K | $825.49K |
| Free cash flow | $73.14M | $31.66M | $74.32M | $68.98M | $99.21M | $26.51M | $50.90M | -$341.00K | $6.17M | $12.70M | $2.32M | -$2.60M |
Frequently Asked Questions About NUTX
What is Nutex Health's annual revenue?
Nutex Health reported revenue of $875.26M for the fiscal year ended Dec 31, 2025.
How fast is Nutex Health's revenue growing?
Revenue was up 82.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 58.6%.
Is Nutex Health profitable?
Yes. Nutex Health reported net income of $180.36M for the fiscal year ended Dec 31, 2025, with a net margin of 20.6%.
How much free cash flow does NUTX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $248.13M minus capital expenditures of $2.53M produced free cash flow of $245.60M.
How much debt does Nutex Health have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $29.17M, short-term debt of $14.08M and cash and equivalents of $185.57M.
NUTX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors